Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
The use of generic DAAs for hepatitis C treatment, Freeman et al 2016
Download PDF
June 28, 2016
/
News
Share
the Post
Related
Posts
Flawed patents on hepatitis C drugs latest to be challenged in global push for access
Generic daclatasvir (60 mg) availability and India market pricing as of 30 January 2016
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
Pricing of Indian generic sofosbuvir, 30th Jan,2016
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Letter from Asian community and treatment advocates to Chief Executive Officer of CHAI regarding the Quick start program and concerns that patients would have to pay for sofosbuvir and diagnostics to be a part of the program in October 2016
Pricing and availability of generic Indian daclatasvir as on 7 March 2016
Asia Pacific Situational Updates on Generic DAAs – June 2017
